All participants will be enrolled through direct contact with collaborating clinical sites. In the first phase this study will strive to enroll 150 participants who are identified as having a suspicious mammogram. Suspicious mammogram will be defined as being rated as Breast Imaging-Reporting and Data System (BIRADS) rating IV or V, undergoing image guided biopsy. BIRADS IV is "Suspicious abnormality" and V is "there is a mammographic appearance which is highly suggestive of malignancy, action should be taken." The goal is to accrue at least 30 cases of invasive cancer confirmed by biopsy, and at least 90 cases of benign or pre-invasive lesion pathology confirmed by biopsy in this first phase study.